Madrid, Spain – 30 August 2025: More patients with hypercholesterolaemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran ...
Inclisiran’s performance in three large randomized trials is now detailed in two papers published in the New England Journal of Medicine—the previously reported data show LDL cholesterol levels ...
About half of all adults prescribed a statin stop taking it within a year. They forget, they dislike the side effects, or they simply tire of swallowing a pill every morning. That dropout rate is not ...
A pooled analysis of clinical trials testing inclisiran (Novartis) confirms the agent’s potent and durable effects on LDL cholesterol and also offers a glimpse of the drug’s potential for lowering the ...
Inclisiran has not been approved by the U.S. Food and Drug Administration, the European Medicines Agency or any other regulatory authority and no conclusions can or should be drawn regarding the ...
More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results